|
|
|
Volumn 18, Issue 11 Suppl 9, 2009, Pages
|
|
Myelodysplastic syndromes: health care management considerations.
a
a
Cigna
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5 AZA 2' DEOXYCYTIDINE;
ANTINEOPLASTIC ANTIMETABOLITE;
AZACITIDINE;
DRUG DERIVATIVE;
ARTICLE;
COOPERATION;
COST CONTROL;
DRUG COST;
ECONOMICS;
HEALTH CARE QUALITY;
HEALTH INSURANCE;
HUMAN;
MYELODYSPLASTIC SYNDROME;
SURVIVAL;
ANTIMETABOLITES, ANTINEOPLASTIC;
AZACITIDINE;
COOPERATIVE BEHAVIOR;
COST CONTROL;
DRUG COSTS;
HUMANS;
MANAGED CARE PROGRAMS;
MYELODYSPLASTIC SYNDROMES;
QUALITY OF HEALTH CARE;
SURVIVAL;
|
|
EID: 77449136017
PISSN: 10623388
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
